A thematic analysis of MDMA-related harm and harm reduction experiences and knowledge in Aotearoa New Zealand
- PMID: 38783300
- PMCID: PMC11112856
- DOI: 10.1186/s12954-024-01024-8
A thematic analysis of MDMA-related harm and harm reduction experiences and knowledge in Aotearoa New Zealand
Abstract
Background: Methylenedioxymethamphetamine (MDMA) is a popular drug worldwide and use is prevalent in Aotearoa New Zealand. Although associated with some significant harms, including fatalities, MDMA is ultimately less harmful than other commonly consumed drugs. We aimed to expand the understanding of MDMA harm and harm reduction strategies from a consumer perspective so that national harm reduction efforts can be better informed.
Methods: We conducted 14 semi-structured focus group discussions including 60 people (aged 18-67, median = 21) who use MDMA in the Southern region of Aotearoa New Zealand to explore their thoughts and experiences regarding MDMA associated harm and harm reduction. Reflexive thematic analysis was conducted from a critical realist perspective.
Results: Five themes were generated; (1) Mindset and setting matters; (2) Looking after your body and mind, not overdoing it; (3) Other substances increase risk and harm; (4) Trusted friends and peers are protective; and (5) Valid information is key for healthy self-determination; and one subtheme 5.1) Drug checking is essential harm reduction.
Conclusions: We discuss the implications for MDMA consumers and aim to inform national drug policy and the harm reduction practices of consumers and organisations, for the ultimate purpose of reducing MDMA-related harm in Aotearoa New Zealand.
Keywords: Aotearoa New Zealand; Harm; Harm reduction; MDMA; Reflexive thematic analysis.
© 2024. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
Harm reduction behaviours and harm experiences of people who use 3,4-methylenedioxymethamphetamine (MDMA) in Aotearoa New Zealand.Harm Reduct J. 2024 Mar 21;21(1):67. doi: 10.1186/s12954-024-00979-y. Harm Reduct J. 2024. PMID: 38515184 Free PMC article.
-
Motivations for Using MDMA (Ecstasy/Molly) among African Americans: Implications for Prevention and Harm-Reduction Programs.J Psychoactive Drugs. 2017 Jul-Aug;49(3):192-200. doi: 10.1080/02791072.2017.1305518. Epub 2017 Apr 13. J Psychoactive Drugs. 2017. PMID: 28406348
-
Risk intentions following pill test scenarios are predicted by MDMA use history and sensation seeking: A quantitative field study at an Australian music festival.Drug Alcohol Rev. 2019 Jul;38(5):473-481. doi: 10.1111/dar.12936. Epub 2019 Jun 7. Drug Alcohol Rev. 2019. PMID: 31173412
-
Neurotoxicity of MDMA: Main effects and mechanisms.Exp Neurol. 2022 Jan;347:113894. doi: 10.1016/j.expneurol.2021.113894. Epub 2021 Oct 13. Exp Neurol. 2022. PMID: 34655576 Review.
-
Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').Drug Saf. 1996 Aug;15(2):107-15. doi: 10.2165/00002018-199615020-00003. Drug Saf. 1996. PMID: 8884162 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical